Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital
Rueda-Lara, A. (Hospital Universitario La Paz (Madrid))
Viñal, D. (Hospital Universitario La Paz (Madrid))
Martínez-Pérez, D. (Hospital Universitario Central de Asturias)
Alameda-Guijarro, M. (Hospital Universitario La Paz (Madrid))
Martin-Montalvo, G. (Hospital Universitario La Paz (Madrid))
Martinez-Recio, Sergio (Institut de Recerca Sant Pau)
Peña-Lopez, J. (Hospital Universitario La Paz (Madrid))
Jiménez-Bou, D. (Hospital Universitario La Paz (Madrid))
Ruíz-Gutiérrez, I. (Hospital Universitario La Paz (Madrid))
García-Leal, A. (Hospital Universitario La Paz (Madrid))
Zwisler-Contreras, P. (Hospital Universitario La Paz (Madrid))
Ghanem, I. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Custodio, A.B. (Centro de Investigación Biomédica en Red de Cáncer)
Pérez-Wert, P. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Gutiérrez-Sainz, L. (Instituto de Investigación Sanitaria del Hospital Universitario La Paz)
Palacios, M.E. (Hospital Universitario La Paz (Madrid))
Feliu, Jaime (Cátedra UAM-AMGEN)
Rodríguez-Salas, N. (Centro de Investigación Biomédica en Red de Cáncer)
Universitat Autònoma de Barcelona

Data:	2025
Resum:	Background: Stage II and III colorectal cancer (CRC) poses a significant challenge due to rising global incidence and mortality rates. Despite advancements in screening and treatment, there's a pressing need for reliable prognostic biomarkers. Tumor budding emerges as a promising marker associated with poor prognosis and higher recurrence. However, its incorporation into clinical guidelines differs when considering adjuvant treatment. This study assesses tumor budding's prognostic value for recurrence in stage II and III CRC, exploring its implications for risk stratification. Methods: This retrospective study encompassed patients with stage II-III CRC at Hospital Universitario La Paz from October 2016 to January 2022. Tumor budding was assessed according to the 2016 ITBCC guidelines and categorized as low, intermediate, or high. The primary outcomes, time to recurrence (TTR) and overall survival (OS), were analyzed using Kaplan-Meier and Cox regression models. Results: A total of 390 patients were included in the final analysis. They were predominantly male (55%) with an average age of 75 years (range 35-95). Fifty percent of patients were stage II. Tumor budding was categorized as low, intermediate, and high in 186 (48%), 110 (28%), and 94 (24%) patients, respectively. After a median follow-up of 46. 1 months, there were 71 recurrences and 96 deaths. Time to recurrence (TTR) was significantly shorter for patients with high tumor budding. At 24 months, freedom from recurrence was 92%, 84%, and 69% for low, intermediate, and high tumor budding groups, respectively. Median TTR was not reached in any group. Multivariate analysis revealed high-grade budding as an independent predictor of recurrence with a hazard ratio (HR) of 2. 39 (P =. 01; 95% CI, [1. 42-4. 04]). Conclusion: Our study highlights the prognostic value of tumor budding in predicting recurrence in both stage II and III colorectal cancer patients, reinforcing its potential as an important biomarker beyond stage II CRC.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adjuvant therapy ; Colorectal cancer ; Prognosis ; Recurrence ; Tumor budding
Publicat a:	The Oncologist, Vol. 30 Núm. 3 (january 2025) , p. oyaf027, ISSN 1549-490X

DOI: 10.1093/oncolo/oyaf027
PMID: 40152315

8 p, 1.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats